Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 163Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Biophore India Pharmaceuticals Pvt Ltd

02 1Beijing Fukangren Biopharmaceutical

03 1Erregierre SpA

04 1Hebei AiYoung Pharmaceutical Technology

05 1Hiray Pharma Solutions

06 1Olon S.p.A

07 1Tianjin Hankang Pharmaceutical Biotechnology

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Urapidil Hydrochloride

About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...

Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-approved API manufacturing facilities, a dedicated intermediate facility, and a R&D laboratory housing 400 scientists, Biophore has positioned itself as a global leader among API companies. It consistently ranks among the top 10 US DMF filers and has obtained over 150 patents worldwide in process and polymorph areas. Biophore's facilities have an impressive track record of successful audits by regulatory bodies such as USFDA, EMEA, ANVISA, COFEPRIS, and WHO GMP.
Biophore

02

2024 ACI Convention
Not Confirmed
arrow
arrow
2024 ACI Convention
Not Confirmed

Urapidil Hydrochloride

About the Company : Beijing Fukangren Biopharmaceutical Technology Co., Ltd. started its drug R&D service in 1999 and is the CRO company with the longest continuous service time in China. Fukangren no...

Beijing Fukangren Biopharmaceutical Technology Co., Ltd. started its drug R&D service in 1999 and is the CRO company with the longest continuous service time in China. Fukangren now has 3 pharmaceutical R&D centers, 1 clinical R&D center, 4 API production bases and 1 preparation production base, forming an end-to-end CDMO service system that can provide customers with drug R&D and production. The development of high-end formulations is a major advantage of Fukangren. Among them, multiple platform projects such as sustained and controlled release formulations.
blank

03

2024 ACI Convention
Not Confirmed
arrow
arrow
2024 ACI Convention
Not Confirmed

Urapidil Hydrochloride

About the Company : ERREGIERRE, a family company, was founded in 1974 and today is one of the leading Italian active pharmaceutical ingredients manufactures for human and veterinary use. In ERREGIE...

ERREGIERRE, a family company, was founded in 1974 and today is one of the leading Italian active pharmaceutical ingredients manufactures for human and veterinary use. In ERREGIERRE we employ more than 220 people and two manufacturing sites, San Paolo d’Argon and Sovere, are both FDA inspected with no 483 form. We provide APIs of the highest quality and we are a reliable partner for the pharmaceutical industry worldwide.
blank

04

2024 ACI Convention
Not Confirmed
arrow
arrow
2024 ACI Convention
Not Confirmed

Urapidil Hydrochloride

About the Company : Hebei AiYoung Pharmaceutical Technology Co., Ltd. is a professional company mainly engaged in chemical APIs and intermediates, including R & D, production, import and export. The c...

Hebei AiYoung Pharmaceutical Technology Co., Ltd. is a professional company mainly engaged in chemical APIs and intermediates, including R & D, production, import and export. The company is committed to building a professional API and intermediate supply platform to provide high-quality intermediate, API and related preparation technologies and other high-quality product services for domestic and foreign pharmaceutical enterprises.
blank

05

2024 ACI Convention
Not Confirmed
arrow
arrow
2024 ACI Convention
Not Confirmed

Urapidil Hydrochloride

About the Company : Hiray Pharma Solutions is an international end-to-end CDMO, facilitating the development and manufacturing of important drug products and key intermediates around the world. We pro...

Hiray Pharma Solutions is an international end-to-end CDMO, facilitating the development and manufacturing of important drug products and key intermediates around the world. We provide the best chemical techniques, control, and manufacturing services to pharmaceutical and innovative enterprises, and a swift path for fine medicine to benefit patients. As an end-to-end CDMO, Hiray can provide on-time, high-quality service for Process R&D, Analytical R&D, Manufacturing, and Quality Control. Hiray operates in strict compliance with, or exceeds, the latest standards for safety, health, and the environment.
blank

06

Olon S.p.A

Italy
2024 ACI Convention
Not Confirmed
arrow

Olon S.p.A

Italy
arrow
2024 ACI Convention
Not Confirmed

Urapidil

About the Company : We produce Active Pharmaceutical Ingredients (APIs) providing integrated full-service capabilities. Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (...

We produce Active Pharmaceutical Ingredients (APIs) providing integrated full-service capabilities. Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (APIs) in our network of facilities allows clients full access to integrated services resulting in faster production and delivery timelines, with one of the most extensive track records. We rely on synthetic and biological processes both for generic and contract development and the manufacturing market, in a full cGMPs environment, following ICH Q7 compliance.
blank

07

2024 ACI Convention
Not Confirmed
arrow
arrow
2024 ACI Convention
Not Confirmed

Urapidil Hydrochloride

About the Company : Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enterprise in China. Focused on generic drugs while venturing into innovative on...

Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enterprise in China. Focused on generic drugs while venturing into innovative ones, the group is dedicated to offering comprehensive solutions to the industry. Presently, Hankang has crafted over 200 varieties for 600+ domestic and international companies, serving 10+ innovative drugs. It has successfully developed more than 10 initial generic drugs, with over 20 varieties endorsed by the top three domestic companies and 30 exceeding a 100 million output value.
blank

Urapidil Manufacturers | Traders | Suppliers

Urapidil Manufacturers, Traders, Suppliers 1